General

Bibliographic Source(s)

  • Cancer Care Ontario Practice Guideline Initiative (CCOPGI). The role of single-agent docetaxel (Taxotere) as a second-line treatment for advanced non-small-cell lung cancer [full report]. Toronto (ON): CCOPGI; 2001 Jan. Various p. (Practice guideline report; no. 7-7-2). [16 references]
  • Logan D, Laurie S, Markman BR, McNeil M, Vincent M, Evans WK, Lung Cancer Disease Site Group. The role of single-agent docetaxel as second-line treatment for advanced non-small-cell lung cancer. Curr Oncol. 2001;8(2):50-9. [16 references]

Identifying Information and Availability

Bibliographic Source(s)

  • Cancer Care Ontario Practice Guideline Initiative (CCOPGI). The role of single-agent docetaxel (Taxotere) as a second-line treatment for advanced non-small-cell lung cancer [full report]. Toronto (ON): CCOPGI; 2001 Jan. Various p. (Practice guideline report; no. 7-7-2). [16 references]
  • Logan D, Laurie S, Markman BR, McNeil M, Vincent M, Evans WK, Lung Cancer Disease Site Group. The role of single-agent docetaxel as second-line treatment for advanced non-small-cell lung cancer. Curr Oncol. 2001;8(2):50-9. [16 references]

Disclaimer

NGC Disclaimer

The National Guideline Clearinghouse™ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.

All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.

Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria.

NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.

Readers with questions regarding guideline content are directed to contact the guideline developer.